1.
Blood
; 2024 Jul 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38985830
RESUMO
Emicizumab improves the procoagulant activity of select loss-of-function FIX variants with likely dysfunctional assembly of the intrinsic Xase complex that cause hemophilia B. FVIII-mimetics may represent an alternative non-factor therapy for select hemophilia B patients.